Open Clinical Trial of Vigabatrin as Add-on Therapy in Severely Intractable Partial Seizures

J Korean Neurol Assoc > Volume 11(1); 1993 > Article

Journal of the Korean Neurological Association 1993;11(1): 85-98.

난치성 부분성 간질 환자에서 Vigabatrin의 병용요법

이병인, 허균,김진수,박수철,성경미,오경자

연세대학교 신경과, 사회과.

Open Clinical Trial of Vigabatrin as Add-on Therapy in Severely Intractable Partial Seizures

B. I. Lee, M.D., K. Huh, M.D., J. S. Kim, M.D., S. C. Park, M.D., K. M. Sung, M.D., K. J. Oh, M.D.

Department of Neurology and Social Art, College of Medicine Yonsei University

Abstract

Open clinical trial of vigabatrin (VG) as add-on therapy was conducted in 32 patients with severely medically intractable partial seizures with or without secondarily generalized tonic-clonic seizures. Study protocol consisted of 2 months of phase I (VG: 2.0gm/day) and 4 months of phase II(VG: 3.0gm/day and/or 4.0gm/day). During the study period. 9 patients were dropped out due to various reasons :3 patients due to side effects, 1 patient due to side effect and lack of effect, 4 patients for lack of effect and 1 patient due to the development of tuberculous meningitis. At the end of study, improvement greater than 50% reduction of seizure frequency was observed in 12 of 28 patieuts (43%) who did not deuelop seuous side effects. Dizziness was the most frequent side effects found in 10 patients. Psychosis was seen in two patients. Upon long term treatment of VG, about 70% of the patients maintained its beneficial effect. Our study suggests that VG is a new antiepileptic drug useful for severely refractory partial seizures.